The Pitman-Moore strain 1503 of rabies virus was developed by Wistar’s researchers in the 1960s and 1970s, and has been successfully used worldwide to generate a post-exposure vaccine for prevention of rabies infection. The virus is harvested from infected human diploid cells, concentrated and then inactivated to generate the vaccine. If stored properly, the vaccine is stable for at least 3.5 years.
Prompt administration, as part of post-exposure treatment, is 100% effective in preventing fatal rabies infection in humans. Wistar’s rabies vaccine has helped to make rabies-related human death a rarity in the U.S. and most other countries.
Certain non-exclusive license rights are available for the development, manufacture, distribution and sale of the Wistar Pitman-Moore 1503 rabies vaccine seed stock.